EUVIMEDEUVIMED entdecken
Übersichtsarbeit

An Insight on the Leading HIV Entry Inhibitors

Ana Salomé Veiga, Nuno C Santos, Miguel A R B Castanho

Recent Patents on Anti-Infective Drug Discovery · 2006

DOI: 10.2174/157489106775244046 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Recent Patents on Anti-Infective Drug Discovery, 2006. Verfasst von Ana Salomé Veiga und 2 weiteren Autor:innen. Beteiligte Einrichtung: Centro de Química e Bioquímica, Faculdade de Ciências da Universidade de Lisboa, Campo Grande Ed. C8, 1749-016 Lisboa, Portugal. Die Arbeit wurde bisher 13-mal zitiert (Crossref).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

The main strategies nowadays to fight AIDS rely on chemical therapy to inhibit the reverse transcriptase or protease of HIV. However, a synthetic 36 amino-acids peptide that blocks the entry of the virus in the target cells (enfuvirtide) has recently reached approval for clinical application. This molecule may probably be just the leader of a new generation of drugs that is about to emerge to interrupt the first step in the HIV life cycle, i.e. preventing the virus from actually entering cells. This paper reviews the enfuvirtide path from clinical trials to the attempts to detail its molecular-level mode of action. It is commonly accepted that this peptide would block the fusion between viral and cell plasma membrane through binding to the N-terminal heptad repeat (NHR) region of the viral protein gp41. However, there has been growing evidence that this model of action may be unrealistic, the action of enfuvirtide being more complex and diverse than initially thought. Membrane-assisted local concentration increase and interference with gp120/co-receptor docking may also contribute for the inhibitory action of the peptide. Selected HIV-entry inhibitors on clinical trials are presented to characterize the future drugs in the market in this class.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

AnimalsClinical Trials as TopicEnfuvirtideHIV Envelope Protein gp41HIV Fusion InhibitorsHIV-1HumansPatents as TopicPeptide FragmentsVirus Internalization

Substanzen

HIV Envelope Protein gp41HIV Fusion InhibitorsPeptide Fragmentspeptide T1249Enfuvirtide

Autor:innen und Institutionen

  • Centro de Química e Bioquímica, Faculdade de Ciências da Universidade de Lisboa, Campo Grande Ed. C8, 1749-016 Lisboa, Portugal.

Zitieren

APA

Veiga, A. S., Santos, N. C., & Castanho, M. A. (2006). An Insight on the Leading HIV Entry Inhibitors. Recent Patents on Anti-Infective Drug Discovery. https://doi.org/10.2174/157489106775244046

Vancouver

Veiga AS, Santos NC, Castanho MA. An Insight on the Leading HIV Entry Inhibitors. Recent Patents on Anti-Infective Drug Discovery. 2006. doi:10.2174/157489106775244046

BibTeX
@article{Veiga2006,
  author = {Veiga, Ana Salomé and Santos, Nuno C and Castanho, Miguel A R B},
  title = {An Insight on the Leading HIV Entry Inhibitors},
  journal = {Recent Patents on Anti-Infective Drug Discovery},
  year = {2006},
  doi = {10.2174/157489106775244046}
}
Kostenlos starten →